XTL Biopharmaceuticals Ltd. (XTLB)Healthcare | Biotechnology | Ramat Gan, Israel | NasdaqCM
2.45 USD
-0.03
(-1.210%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 2.45 Short-term: ★☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 4:06 p.m. EDT
XTL Biopharmaceuticals Ltd. (XTLB) is currently trading at a price of $2.37, which is near its 52-week low of $2.12. The stock has been volatile, with a 50-day average of $2.98 and a 200-day average of $4.22, indicating a significant decline in price over the past few months. The recent news of a Nasdaq delisting notice and the insolvency of a subsidiary have likely contributed to the downward trend. Additionally, the company is facing negative fundamentals, with negative earnings, return on assets, and return on equity. The stock has no dividend history, and the forecasting model predicts a slight decline in price over the next 45 days. Short-term traders might consider buying on dips, but the overall outlook is bearish. Long-term investors should avoid this stock due to its poor fundamentals and uncertain future. Dividend investors should also avoid this stock as it has no dividend history. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.253888 |
| AutoETS | 0.266947 |
| AutoARIMA | 0.268130 |
| MSTL | 0.278353 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 21.85 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.196 |
| Excess Kurtosis | -1.26 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.4 |
| Market Cap | 5,795,739 |
| Beta | 0.68 |
| Website | https://www.xtlbio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.511811 |
| Address1 | 26 Ben-Gurion St. |
| All Time High | 2,400.0 |
| All Time Low | 2.12 |
| Ask | 3.13 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 7,870 |
| Average Daily Volume3 Month | 14,964 |
| Average Volume | 14,964 |
| Average Volume10Days | 7,870 |
| Beta | 0.677 |
| Bid | 1.75 |
| Bid Size | 2 |
| Book Value | -0.0 |
| City | Ramat Gan |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.45 |
| Current Ratio | 0.7 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 2.6 |
| Day Low | 2.3653 |
| Display Name | XTL Biopharmaceuticals |
| Dividend Date | 1,486,684,800 |
| Ebitda Margins | 0.0 |
| Enterprise To Revenue | 2,257.916 |
| Enterprise Value | 2,185,662,208 |
| Eps Trailing Twelve Months | -3.6 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.9048 |
| Fifty Day Average Change | -0.4547999 |
| Fifty Day Average Change Percent | -0.15656841 |
| Fifty Two Week Change Percent | -51.181103 |
| Fifty Two Week High | 10.28 |
| Fifty Two Week High Change | -7.83 |
| Fifty Two Week High Change Percent | -0.76167315 |
| Fifty Two Week Low | 2.12 |
| Fifty Two Week Low Change | 0.33000016 |
| Fifty Two Week Low Change Percent | 0.15566047 |
| Fifty Two Week Range | 2.12 - 10.28 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,125,581,400,000 |
| Float Shares | 274,560,296 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 10 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -2.32851 |
| Gross Profits | -2,254,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.38461 |
| Held Percent Institutions | 0.03586 |
| Implied Shares Outstanding | 2,365,608 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Language | en-US |
| Last Fiscal Year End | 1,735,603,200 |
| Last Split Date | 1,774,396,800 |
| Last Split Factor | 1:4 |
| Long Business Summary | XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel. |
| Long Name | XTL Biopharmaceuticals Ltd. |
| Market | us_market |
| Market Cap | 5,795,739 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_36775 |
| Most Recent Quarter | 1,751,241,600 |
| Net Income To Common | -6,308,000 |
| Next Fiscal Year End | 1,767,139,200 |
| Non Diluted Market Cap | 5,994,432 |
| Open | 2.6 |
| Operating Margins | -8.53578 |
| Payout Ratio | 0.0 |
| Peg Ratio | 2.27 |
| Phone | 972 3 611 6600 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 2.45 |
| Post Market Time | 1,776,457,553 |
| Previous Close | 2.48 |
| Price Hint | 4 |
| Price To Sales Trailing12 Months | 5.987334 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.459 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.029999971 |
| Regular Market Change Percent | -1.2096763 |
| Regular Market Day High | 2.6 |
| Regular Market Day Low | 2.3653 |
| Regular Market Day Range | 2.3653 - 2.6 |
| Regular Market Open | 2.6 |
| Regular Market Previous Close | 2.48 |
| Regular Market Price | 2.45 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 4,049 |
| Return On Assets | -2.40561 |
| Return On Equity | -5.7712703 |
| Revenue Per Share | 0.4 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 2,365,608 |
| Shares Percent Shares Out | 0.0014 |
| Shares Short | 3,369 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 16,634 |
| Short Name | XTL Biopharmaceuticals Ltd. |
| Short Percent Of Float | 0.0137 |
| Short Ratio | 0.37 |
| Source Interval | 15 |
| Symbol | XTLB |
| Total Cash | 259,000 |
| Total Cash Per Share | 0.0 |
| Total Debt | 86,000 |
| Total Revenue | 968,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.6 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.1708 |
| Two Hundred Day Average Change | -1.7208002 |
| Two Hundred Day Average Change Percent | -0.41258273 |
| Type Disp | Equity |
| Volume | 4,049 |
| Website | https://www.xtlbio.com |
| Zip | 5,112,001 |